Quick Facts

• Primary Use: Management of Leishmaniasis
• Therapeutic Scope: Addresses symptoms associated with visceral, cutaneous, and mucosal types of Leishmaniasis.
• Role: Used as an anti-protozoan agent to treat certain parasitic infections.

Sodium Stibogluconate is a medication used in the management of Leishmaniasis, a parasitic disease spread by sandfly bites. It is an anti-protozoan agent that may assist with the treatment of the various forms of this infection. The therapeutic use of the compound encompasses addressing symptoms of visceral leishmaniasis, which affects internal organs. It is also used to manage cutaneous leishmaniasis, which primarily involves skin lesions, and mucosal leishmaniasis.

This medication is made available through specific programs, such as those for specific government or military entities, due to the limited commercial market in certain regions. International guidance exists regarding the use of this agent in areas where the disease is prevalent.

Eligibility Map: Who can and cannot use Sodium Stibogluconate — official regulatory information

Eligibility scope

Classification	Population Rule	Status
Use Allowed	Adult and pediatric patients for the approved indication.	Established
Contraindicated	Patients with known hypersensitivity to antimonials.	Prohibited
Contraindicated	Patients with significant renal impairment or renal failure.	Prohibited
Contraindicated	Patients with severe cardiac disease or severe liver disease.	Prohibited
Contraindicated	Pregnant women and breastfeeding women.	Prohibited
Restricted Use	Patients with pre-existing organ dysfunction (renal, hepatic, cardiac) require intensive monitoring.	Conditional

Age-related eligibility rules: The medicine is used in both adult and pediatric populations. Official protocols require specific precautions and monitoring when treating older adults.

Eligibility-related restrictions: Females and males of reproductive potential must use effective methods to prevent pregnancy or fathering a child for a specified period during and after therapy, as mandated by controlled use protocols.

Connection to the overall eligibility profile: Regulatory documents define the eligibility for Sodium Stibogluconate primarily through absolute contraindications linked to reproductive status, hypersensitivity, and the functional status of critical organ systems (renal, hepatic, and cardiac). Eligibility for use is formally established only for patients without these specific regulatory exclusions.

Interactions with other medicines and products

The interaction profile of Sodium Stibogluconate is primarily defined by pharmacodynamic interactions that result in additive cardiac toxicity. Regulatory documentation identifies specific drug classes and agents that may lead to an enhanced risk of serious cardiac effects, including QTc prolongation and arrhythmias.

Documented Pharmacodynamic Interactions

Substance Category	Official Interaction Outcome
Amphotericin B deoxycholate	May enhance cardiotoxic effects and increase the risk of fatal cardiac arrhythmias.
QTc-prolonging Agents	May enhance the drug's QTc-prolonging effect due to additive cardiac risk.
Other Antimonial Drugs	Potential for additive antimony intoxication, including cardiac abnormalities.

Required Timing and Condition Notes

Regulatory authorities suggest a 14-day resting period between the cessation of Sodium Stibogluconate treatment and the initiation of Amphotericin B deoxycholate in retreatment regimens for visceral leishmaniasis to mitigate cardiac risk. The cardiac risk from these pharmacodynamic interactions is specifically noted to be magnified in individuals with pre-existing risk factors, such as documented cardiovascular disease or a history of ventricular arrhythmias. Official documentation does not report formal pharmacokinetic interactions involving CYP enzymes, drug transporters, or specific interactions with food, alcohol, or herbal products.

Activation and Metabolic Shutdown

Sodium Stibogluconate acts as a prodrug that is chemically reduced by the parasite's own enzymes into the active, toxic trivalent antimony (SbIII) form. This activated species targets and binds to thiol-dependent enzymes critical for the parasite's survival, effectively blocking its main energy pathways (glycolysis and fatty acid oxidation). This rapid metabolic inhibition starves the parasite of the necessary energy (ATP) required for growth and function, initiating its demise.

---

Disruption of Redox Defenses

Complementary to metabolic shutdown, the active antimony compounds bind to and compromise the parasite's unique antioxidant system, most notably trypanothione. By neutralizing this crucial defense, the drug causes a surge of toxic oxidative stress within the parasitic cell. This internal poisoning severely damages parasitic macromolecules and forces the cell into an irreversible decline, resulting in the cessation of its viability.

---

️ Host Immune Potentiation

Beyond its direct leishmanicidal action, the drug supports the host's defense by activating resident macrophages. This mechanism enhances the cell's respiratory burst—the generation of destructive chemical species—thereby increasing the ability of the host's immune system to clear the remaining parasitic load from affected tissues. This contributes to a dual mechanism of action against the foreign cells.

Official Administration Guidelines

Sodium Stibogluconate is supplied as a sterile solution of 100 mg pentavalent antimony per mL and must be administered parenterally. The officially approved routes for systemic treatment include intravenous (IV) injection or slow infusion and intramuscular (IM) injection. For localized cutaneous lesions, the medicine may also be given via intralesional injection.

Dosing and Frequency

The standard systemic dosing regimen is bodyweight-based, with a daily prescription of 20 mg of pentavalent antimony per kg of bodyweight (20 mg Sb/ kg/ day). This bodyweight-based dose is applied to both adult and pediatric patients. This dose must be given once daily, with no provision for divided use. Historically, some prescribing information included a maximum daily dose of 850 mg of antimony.

Treatment duration is a fixed course length defined by the infection type. Visceral and mucocutaneous leishmaniasis regimens are generally set for 28 days, while systemic therapy for cutaneous leishmaniasis is typically for 20 days.

Administration Conditions

Specific preparation procedures are required: the solution must be drawn up through a sterile filter immediately before use. Intravenous delivery must proceed as a slow infusion, often specified over a minimum of five minutes, and must be administered in a supervised healthcare setting. The slow infusion rate and the instruction to immediately cease administration if the patient develops coughing or central chest pain define key official procedural conditions.

Research evidence / Overview of studies for Sodium Stibogluconate

The research on Sodium Stibogluconate is primarily based on clinical studies conducted in regions where the Leishmania parasite is active. The body of evidence, which includes controlled trials, comparative studies, and observational reports, contributes to understanding the patterns observed in the study populations. This research has been applied in studies examining how symptoms change over time in conditions associated with acute or disruptive episodes.

---

Evidence for use in Visceral Leishmaniasis (Kala-azar)

Research has extensively examined Sodium Stibogluconate in the context of Visceral Leishmaniasis (VL). Studies exploring this use include Randomized Controlled Trials (RCTs) and Observational Cohort Studies. Researchers monitored several key outcomes, including the assessment of the Initial Response Rate measured at the end of treatment, the Final Response Rate assessed several months later, and the subsequent tracking of Relapse Frequency. The research focused on patient cohorts in endemic areas, including both adult and pediatric populations, as well as specific groups such as HIV-negative patients. Studies explored the medicine both as a single agent and as part of combination therapy regimens.

Studies tracked and reported measurements related to the assessment of response and the frequency of relapse. However, the data show patterns related to variability in reported outcomes. This variability was observed in some studies and was associated with specific geographical areas and the varying parasite strains encountered. Evidence remains limited regarding the long-term outcomes and the durability of the response beyond the typical six-month follow-up period.

---

Evidence for use in Cutaneous Leishmaniasis

The research for Cutaneous Leishmaniasis (CL) is based on a structure that includes Randomized Controlled Trials (RCTs) and Meta-analyses of Controlled Trials. Studies monitored the tracking of clinical outcomes, such as measuring the Clinical Response Rate (based on lesion healing), monitoring Parasitological Clearance, and tracking Lesion Size Reduction. Patient populations in both New World (American) and Old World settings were studied, with research often differentiating cohorts based on the specific causative parasite species.

---

Current Research Gaps and Uncertainties

The evidence contributes to understanding what has been observed—and what remains uncertain—about this medicine. The evidence quality varies across studies, and findings were often mixed regarding the consistency of outcomes. This variability is associated with factors like the specific geographical area or the species of the parasite. Comparative evidence is lacking for certain treatment scenarios. Research is ongoing to examine the patterns observed when comparing the medicine's use in monotherapy versus combination regimens. The research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
2. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies
3. ASTMH/IDSA Clinical Practice Guidelines for the Diagnosis and Treatment of Leishmaniasis (Reference for overall context and evidence structure)

Common questions about Sodium Stibogluconate (FAQ)

---

Q: Why is this medicine given by injection and not as a pill?

A: Sodium Stibogluconate is supplied only as a sterile solution for injection. Official product information indicates that this route of administration (parenteral preparation) is necessary because the compound has specific properties, such as potential poor oral absorption. Direct injection is required to deliver an appropriate amount for treatment.

---

Q: How long after treatment is finished do the side effects usually go away?

A: Official safety data indicates that many of the temporary changes noted during treatment, particularly the laboratory abnormalities like elevated liver enzymes, are often reversible once the medicine is stopped. The duration for the complete resolution of all reported side effects may vary.

---

Q: How long does the full course of treatment typically last (descriptive)?

A: The duration of the active treatment is set based on the type of parasitic infection being treated. The standard systemic therapy for visceral or mucocutaneous infections is typically set for 28 days, while systemic therapy for cutaneous infections is usually 20 days.

---

Q: Are there ongoing studies looking at new uses for Sodium Stibogluconate?

A: Yes, regulatory-backed research platforms list studies and investigations into the compound's properties beyond its primary approved use. This includes past and ongoing research exploring its potential effects in other areas, such as its activity as an anti-tumor agent.

---

Q: What is the difference between Sodium Stibogluconate and meglumine antimoniate?

A: Both Sodium Stibogluconate (SSG) and meglumine antimoniate (MA) belong to the class of pentavalent antimonial compounds used to treat the same infections. They are chemically distinct formulations; SSG is an antimony sodium gluconate complex, while MA is an antimony meglumine gluconate complex.

---

Q: Is Sodium Stibogluconate used to treat any other conditions besides its main indication?

A: Official documents list its primary indication for the treatment of various forms of leishmaniasis. However, the compound has also been the subject of regulatory-reviewed research for potential effects in other areas, such as its activity as an anti-tumor agent.

---

Q: Are there known effects on fertility described for Sodium Stibogluconate?

A: Official protocols require that individuals of reproductive potential use effective methods to prevent pregnancy or fathering a child during and for a specified time after therapy. This precaution is mandated due to potential risks to the fetus and the lack of comprehensive safety data regarding its impact on reproductive health.

---

Q: What is the difference between Sodium Stibogluconate and older antimony compounds?

A: Sodium Stibogluconate is classified as a pentavalent antimony (SbV) derivative. It differs chemically from older antimony compounds that may have used a trivalent antimony (SbIII) structure. The medicine acts as a prodrug, which means it requires conversion to the active SbIII form inside the parasite to work.

---

Q: Is it common to feel tired while taking this medicine?

A: Regulatory safety documents classify general tiredness, also sometimes described as lethargy or malaise, as a commonly reported adverse effect associated with the use of this medicine.

---

Q: Does alcohol interact negatively with Sodium Stibogluconate?

A: Official regulatory documentation has not reported formal pharmacokinetic interactions specifically involving alcohol with this medicine.

---

Q: Are there any common foods or drinks to avoid while taking it?

A: Official regulatory documentation has not reported formal pharmacokinetic interactions specifically involving common food or drinks with this medicine.

---

Q: Can Sodium Stibogluconate interact with over-the-counter pain relievers?

A: Official documentation warns against combining this medicine with any QTc-prolonging agents due to the enhanced risk of serious cardiac effects. Official information advises reviewing the full list of medications, including over-the-counter products, that fall under this classification.

---

Q: Can Sodium Stibogluconate be used in children?

A: Yes, official protocols confirm the medicine is used in pediatric populations. The medicine is used in children, following the same bodyweight-based dosing regimen as for adults, although specific monitoring may be required.

---

Q: Is this medicine used in older adults?

A: The medicine is used in both adult and older adult populations. Official protocols require that specific precautions and increased monitoring be applied when treating older adults, due to a higher potential for pre-existing organ dysfunction.

---

Q: Is Sodium Stibogluconate considered a strong medicine?

A: The medicine is classified as a highly specialized antiprotozoal agent. Its importance is underscored by its inclusion on the World Health Organization's (WHO) Essential Medicines List for its targeted efficacy against the Leishmania parasite.

---

Q: Is there a generic version of Sodium Stibogluconate?

A: Sodium Stibogluconate is the officially recognized generic name for the active ingredient itself. While it may be marketed under specific brand names in certain regions (e.g., Pentostam), the name Sodium Stibogluconate refers to the base drug product.

---

Q: How is the medicine distributed or obtained globally?

A: Given its specialized nature and inclusion on the WHO Essential Medicines List, its availability is often controlled by public health programs in endemic regions. In some countries, it may be available only through controlled access or special regulatory protocols.

---

Q: Why is it sometimes hard to find information about this drug?

A: This medicine is highly specialized, primarily targeting parasitic infections prevalent in specific endemic regions. Its use in non-endemic countries is often restricted or managed under controlled-use protocols, leading to less widespread public information compared to common medications.

---

Q: What is the source of the drug's name, Sodium Stibogluconate?

A: The name is derived directly from its chemical composition. 'Sodium' refers to the sodium cation, 'stibo-' is the prefix for the element antimony, and 'gluconate' refers to the gluconic acid derivative component in the complex.

---

Q: Is it normal to feel a stinging sensation at the injection site?

A: Official administration procedures mandate that intravenous delivery must proceed as a slow infusion over a minimum of five minutes, and the procedure must be in a supervised healthcare setting. This regulation suggests the need to manage potential local issues, such as pain or discomfort, at the injection site.

---

Q: What happens if a dose of Sodium Stibogluconate is missed (non-directive)?

A: Official guidance for critical daily medications generally advises patients not to take a double dose to make up for a missed dose. The treating healthcare professional should be contacted as soon as possible for instruction on how to proceed with the remaining course.

---

Q: Can Sodium Stibogluconate cause changes in my blood tests?

A: Yes, official safety information indicates the medicine can cause changes in blood tests. The most common findings are elevated levels of serum amylase, lipase, and hepatic transaminases. Official documentation also notes that use can cause temporary thrombocytopenia and leucopenia.

---

Q: What is the risk of an allergic reaction to Sodium Stibogluconate?

A: The medicine is strictly contraindicated in patients with a known hypersensitivity to antimonials. The risk of a severe allergic reaction is a known and serious possibility, and regulatory protocols emphasize its absolute contraindication in cases of known hypersensitivity.

---

Q: Do I need to stay in the hospital to receive Sodium Stibogluconate?

A: Official administration procedures state that the medicine must be administered in a supervised healthcare setting. This is required due to the need for a slow infusion rate and the instruction to immediately cease administration if the patient develops specific symptoms like chest pain or coughing.

---

Q: What should I do if the injection site becomes very red or swollen (non-advice)?

A: Official protocols state that any notable local reaction, such as swelling or redness at the injection site, should be brought to the attention of the healthcare professional managing the administration. The medicine is administered in a supervised healthcare setting with strict monitoring requirements.

---

Q: How is the safety of Sodium Stibogluconate monitored after it is approved?

A: The safety profile of the medicine is monitored through pharmacovigilance and post-marketing surveillance systems established by regulatory bodies globally. These systems are responsible for collecting and analyzing reports of adverse reactions after the medicine has been made available for use.

---

Q: Is the medicine temperature sensitive?

A: Yes, official requirements state the medicine is temperature sensitive. It must be stored below 25 C (77 F) and must not be frozen to maintain its quality, stability, and effectiveness.

---

Q: Why do regulatory bodies classify Sodium Stibogluconate the way they do?

A: Regulatory bodies classify the medicine based on its primary function as an Antiprotozoal Agent and its specific chemical nature as a Pentavalent Antimonial. Its inclusion on the WHO Essential Medicines List is due to its targeted efficacy against the Leishmania parasite and its critical role in public health.

---

Q: Is Sodium Stibogluconate effective against different strains of the parasite?

A: Research indicates that findings related to the medicine's effectiveness have shown variability in reported outcomes. This variability has been associated with factors such as the specific geographical area and the different species of the Leishmania parasite encountered.

---

Storage and Disposal Requirements

Sodium stibogluconate injection must be stored according to strict regulatory guidelines to maintain its quality.

Detail	Requirement
Storage Temperature	Store below 25 C (mathbf77 F).
Protection	Keep the medicine in its original outer carton to protect from light.
Prohibited Conditions	Do not freeze the solution.
In-Use Stability	If a multi-dose container is accessed, the contents should not be used more than 1 month from the time of the first dose.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal

Disposal of unused or expired product must be done in accordance with local, regional, and national regulations. This medicine has an environmental hazard classification, meaning it is mandatory to avoid release to the environment and do not allow it to enter sewers or water systems. All associated used needles and syringes must be placed in a puncture-proof sharps disposal container.